Evidence map›Paper›PMID 27579828›Full record

ReviewJournal of managed care & specialty pharmacy2016

Pharmacy Benefits Management in the Veterans Health Administration Revisited: A Decade of Advancements, 2004-2014.

Sherrie L Aspinall, Mariscelle M Sales, Chester B Good, Vincent Calabrese, Peter A Glassman, Muriel Burk, Von R Moore, Melinda M Neuhauser, Lori Golterman, Heather Ourth and 2 more

Abstract readReview
In one paragraph

Review in Journal of managed care & specialty pharmacy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Early Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Value of a Pharmacy-Adjudicated Community Care Prior Authorization Drug Request Service.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022
    Article
  8. Article
  9. Interventions to Increase Leukocyte Testing during Treatment with Dimethyl Fumarate.International journal of environmental research and public health · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Multiple Sclerosis Medications in the VHA: Delivering Specialty, High-Cost, Pharmacy Care in a National System.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020
    Article
  14. Article
  15. Observational
  16. Responsiveness of Veterans Affairs Health Care System to Zolpidem Safety Warnings.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sherrie L Aspinall1 VA Pharmacy Benefits Management Services, Hines, Illinois; VA Pittsburgh Healthcare System, Center for Health Equity Research and Promotion; and University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.
Mariscelle M Sales2 VA Pharmacy Benefits Management Services, Hines, Illinois.
Chester B Good3 VA Pittsburgh Healthcare System, Center for Health Equity Research and Promotion, University of Pittsburgh School of Pharmacy and School of Medicine, Pittsburgh, Pennsylvania, and VA Pharmacy Benefits Management Services, Washington, DC.
Vincent Calabrese2 VA Pharmacy Benefits Management Services, Hines, Illinois.
Peter A Glassman4 VA Greater Los Angeles Healthcare System, Department of Medicine, and University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California.
Muriel Burk2 VA Pharmacy Benefits Management Services, Hines, Illinois.
Von R Moore2 VA Pharmacy Benefits Management Services, Hines, Illinois.
Melinda M Neuhauser2 VA Pharmacy Benefits Management Services, Hines, Illinois.
Lori Golterman5 VA Pharmacy Benefits Management Services, Washington, DC.
Heather Ourth2 VA Pharmacy Benefits Management Services, Hines, Illinois.
Michael A Valentino5 VA Pharmacy Benefits Management Services, Washington, DC.
Francesca E Cunningham2 VA Pharmacy Benefits Management Services, Hines, Illinois.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, the Department of Veterans Affairs (VA) Pharmacy Benefits Management Services (PBM) has enhanced its formulary management activities and added programs to ensure that the national drug plan continues to meet the pharmacy needs of veterans and to promote safe and appropriate drug therapy in the face of rising medication expenditures. This article describes the broad range of services provided by the VA PBM that work in partnership to deliver a high-quality and sustainable pharmacy benefit for veterans. In support of formulary management, VA PBM pharmacists prepare extensive clinical guidance documents (e.g., drug monographs and criteria for use) that are used by physicians and pharmacists with operational and clinical oversight of the VA national formulary. The VA PBM has utilized various contracting techniques and continually evaluates drug utilization data to identify opportunities for potential savings. Remarkably, since before 2004, the average acquisition cost for a 1-month supply of medication has remained fairly stable at approximately $13-$15. Two new VA PBM programs are the VA Center for Medication Safety (VA MedSAFE) and the Clinical Pharmacy Practice Office (CPPO). VA MedSAFE is a comprehensive pharmacovigilance program focused on the detection, assessment, and prevention of adverse drug events, and CPPO is dedicated to improving safe and appropriate medication use by supporting and expanding clinical pharmacy practice. Moving forward, the VA PBM will consider new initiatives to stay at the forefront of providing quality care while maintaining economic viability. DISCLOSURES: No outside funding supported this research. This work was supported by VA Pharmacy Benefits Management Services (VA PBM), Hines, Illinois, and VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. Glassman is co-director of the VA Center for Medication Safety, which is part of the VA PBM. He is also part of the Medical Advisory Panel for the VA PMB. All other authors are employed by the VA PBM. The views expressed in this article are those of the authors, and no official endorsement by the U.S. Department of Veteran Affairs or the U.S. government is intended or should be inferred. Study concept and design were contributed by Valentino, Cunningham, Good, Aspinall, and Sales. Calabrese and Ourth took the lead in data collection, along with Good, Cunningham, Aspinall, Sales, Burk, Moore, Neuhauser, and Golterman. Data interpretation was performed by Burk, Newhauser, and Golterman, along with Glassman, Calabrese, Moore, and Ourth. The manuscript was written by Aspinall and Sales, along with Burk, Newhauser, Golterman, Ourth, and Cunningham. Good, Glassman, and Moore revised the manuscript, along with Calabrese, Valentino, and Aspinall.

Indexed as

Pharmacopoeias as TopicHumansInsurance BenefitsPharmacistsPharmacy Service, HospitalTime FactorsUnited StatesUnited States Department of Veterans AffairsVeterans Health

Identifiers

PMID27579828
PMCPMC10398159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.